SecBot SecBot
8-K ·Filed Feb 25, 2026

LIVN

LivaNova PLC
BULLISH
Impact 7/10
Horizonmonths Processed8mo ago SEC0001639691-26-000006
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The combination of strong organic growth, improved guidance, and positive regulatory developments (Medicare reimbursement increase and FDA approval) suggests sustainable momentum. Traders should monitor execution on the OSA market entry and whether the company can maintain margin expansion while investing in growth.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$70.29
T+0 close · Feb 25, 2026 · via day close
Latest settled
+4.87%
T+60 · $73.71
Vs SPY
−2.08%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $70.29entry
  2. T+1 · 9mo ago +1.01%α +1.56% · $71.00
  3. T+5 · 9mo ago −7.16%α −6.06% · $65.26
  4. T+20 · 8mo ago −9.94%α −4.71% · $63.30
  5. T+60 · 6mo ago +4.87%α −2.08% · $73.71
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

LivaNova reported strong full-year 2025 results with double-digit revenue growth and improved margins, driven by both Cardiopulmonary and Neuromodulation segments. Despite a GAAP loss due to a $365.6 million environmental liability, adjusted earnings grew 15.4%. The company issued 2026 guidance for 6-7% revenue growth and $4.15-$4.25 adjusted EPS, supported by increased Medicare reimbursement and FDA approval for a new digital health platform.

Key Financial Metrics

Revenue
$1.4K
+10.7% YoY
Adj. EPS
$3.90
GAAP: $-4.45
Guidance
6.0%-7.0% (constant-currency)
issued
Free Cash Flow
$183.30
Gross Margin
67.7%

Key Facts

  • Full-year 2025 revenue grew 10.7% to $1.39 billion, with Cardiopulmonary up 14.9% and Neuromodulation up 7.0%
  • Full-year adjusted EPS was $3.90, up 15.4% from $3.38 in 2024
  • GAAP loss of $4.45 per share due to $365.6 million SNIA environmental liability expense
  • 2026 guidance: 6-7% constant-currency revenue growth and $4.15-$4.25 adjusted EPS
  • Received increased Medicare reimbursement for VNS Therapy procedures, with payments rising ~48% for new implants
  • Received FDA approval for cloud-based digital health platform

Financial Impact

Revenue growth of 10.7% and adjusted EPS growth of 15.4% in 2025, with 2026 guidance projecting continued growth

revenueepsmarginscash flow

Segment Breakdown

SegmentRevenueGrowth
Cardiopulmonary$785.40+14.9%
Neuromodulation$592.80+7.0%

Risk Factors

  • One-time $365.6 million environmental liability expense impacted GAAP results
  • Adjusted free cash flow guidance for 2026 ($160-180M) is below 2025's $183.3M, suggesting potential investment needs
  • Dependence on successful commercialization of new OSA opportunity

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001639691-26-000006
Document: livn-20260225.htm0001639691-26-000006
Document: 0001639691-26-000006-index-headers.html0001639691-26-000006
Document: 0001639691-26-000006-index.html0001639691-26-000006
Document: 0001639691-26-000006.txt0001639691-26-000006
CONTEXT: Previous Earnings (2026-02-25)0001639691-26-000006

Track record

10 reports on LIVN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago 144 Neutral 2/10 Entry $91.32 Now $92.44 +1.23% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $90.98 Now $92.44 +1.60% settles Feb 9
  3. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $91.14 Now $92.44 +1.43% settles Feb 3
  4. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $94.19 Now $92.44 −1.86% settles Feb 2
  5. Sep 14, 20269w ago Insider Cluster Neutral 2/10 Entry $79.47 Now $92.44 +16.32% settles Dec 9
  6. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $78.93 Now $92.44 +17.12% settles Dec 3
  7. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $78.15 to $81.52 Now $92.44 +18.29% ▲ +4.32% +4.13% vs SPY
  8. May 6, 202627w ago 8-K Bullish 8/10 Entry $66.26 to $80.14 Now $92.44 +39.51% ▲ +20.95% +18.89% vs SPY
  9. Apr 29, 202628w ago DEFA14A Neutral 2/10 Entry $58.92 to $78.19 Now $92.44 +56.89% ▲ +32.71% +28.59% vs SPY
  10. Feb 25, 202637w ago 8-K Bullish 7/10 Viewing Entry $70.29 to $73.71 Now $92.44 +31.51% ▲ +4.87% −2.08% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 9h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026